International consensus on diagnosing and managing pancreatic serous and mucinous cystic neoplasms

2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.16931/1995-5464.2025-3-12-30
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.